PMC:7113610 / 23112-23406
Annnotations
LitCovid-PubTator
| Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
|---|---|---|---|---|---|
| 803 | 66-76 | Species | denotes | SARS-CoV-2 | Tax:2697049 |
| 810 | 193-200 | Disease | denotes | Johnson | MESH:C535882 |
| 811 | 203-210 | Disease | denotes | Johnson | MESH:C535882 |
LitCovid-PD-MONDO
| Id | Subject | Object | Predicate | Lexical cue | mondo_id |
|---|---|---|---|---|---|
| T241 | 66-74 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
| T242 | 66-70 | Disease | denotes | SARS | http://purl.obolibrary.org/obo/MONDO_0005091 |
LitCovid-sentences
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T169 | 0-294 | Sentence | denotes | There are many companies working for the development of effective SARS-CoV-2 vaccines, such as Moderna Therapeutics, Inovio Pharmaceuticals, Novavax, Vir Biotechnology, Stermirna Therapeutics, Johnson & Johnson, VIDO-InterVac, GeoVax-BravoVax, Clover Biopharmaceuticals, CureVac, and Codagenix. |
LitCovid-PMC-OGER-BB
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T637 | 66-76 | SP_7 | denotes | SARS-CoV-2 |
| T638 | 124-139 | CHEBI:52217;CHEBI:52217 | denotes | Pharmaceuticals |
| T639 | 251-269 | CHEBI:33694;CHEBI:33694 | denotes | Biopharmaceuticals |
| T76622 | 66-76 | SP_7 | denotes | SARS-CoV-2 |
| T67024 | 124-139 | CHEBI:52217;CHEBI:52217 | denotes | Pharmaceuticals |
| T82110 | 251-269 | CHEBI:33694;CHEBI:33694 | denotes | Biopharmaceuticals |